A Phase 1 interventional study of Pramipexole Dihydrochloride and Pramipexole Dihydrochloride in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-04-30.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The object of this study was to compare the relative bioavailability (rate and extent of absorption) of Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc. with that of Mirapex® Tablets 0.25 mg distributed by Boehringer Ingelheim Pharmaceuticals, Inc. following a single oral dose in healthy adults under non-fasting conditions.
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA Bioequivalence Statistical Methods
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pramipexole Dihydrochloride 0.25 mg Tablets
Drug: Pramipexole Dihydrochloride
Mirapex® 0.25 mg Tablets
Drug: Pramipexole Dihydrochloride
0.25 mg Tablet
0.25 mg Tablet
Also known as: Mirapex®
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
Bioequivalence based on Cmax.
Time frame: Blood samples collected over a 48 hour period.
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Bioequivalence based on AUC0-t.
Time frame: Blood samples collected over a 48 hour period.
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
Bioequivalence based on AUC0-inf.
Time frame: Blood samples collected over a 48 hour period.
| Milestone | Test (Pramipexole Dihydrochloride) First | Reference (Mirapex®) First |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| Milestone | Test (Pramipexole Dihydrochloride) First | Reference (Mirapex®) First |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| Milestone | Test (Pramipexole Dihydrochloride) First | Reference (Mirapex®) First |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
Bioequivalence based on Cmax.
| ng/mL | Test (Pramipexole Dihydrochloride) | Reference (Mirapex®) |
|---|---|---|
| Cmax (Maximum Observed Concentration of Drug Substance in Plasma) | 0.61 ± 0.22 | 0.54 ± 0.10 |
Bioequivalence based on AUC0-t.
| ng*h/mL | Test (Pramipexole Dihydrochloride) | Reference (Mirapex®) |
|---|---|---|
| AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 5.86 ± 1.18 | 5.68 ± 1.36 |
Bioequivalence based on AUC0-inf.
| ng*h/mL | Test (Pramipexole Dihydrochloride) | Reference (Mirapex®) |
|---|---|---|
| AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) | 6.27 ± 1.21 | 6.17 ± 1.40 |
Collected over Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test (Pramipexole Dihydrochloride) First | — | 0/24 (0%) | 2/24 (8.3%) |
| Reference (Mirapex®) First | — | 0/24 (0%) | 4/24 (16.7%) |
| Event | Test (Pramipexole Dihydrochloride) First | Reference (Mirapex®) First |
|---|---|---|
| DizzinessGeneral disorders | 2/24 | 0/24 |
| HeadacheGeneral disorders | 0/24 | 2/24 |
| NauseaGeneral disorders | 0/24 | 2/24 |
| NervousnessGeneral disorders | 2/24 | 0/24 |
| Age, Categorical(Participants) | Test (Pramipexole Dihydrochloride) First | Reference (Mirapex®) First | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 12 | 24 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Test (Pramipexole Dihydrochloride) First | Reference (Mirapex®) First | Total |
|---|---|---|---|
| Female | 5 | 7 | 12 |
| Male | 7 | 5 | 12 |
| Race/Ethnicity, Customized(participants) | Test (Pramipexole Dihydrochloride) First | Reference (Mirapex®) First | Total |
|---|---|---|---|
| Caucasian | 10 | 12 | 22 |
| Black | 1 | 0 | 1 |
| Native American | 1 | 0 | 1 |
| Region of Enrollment(participants) | Test (Pramipexole Dihydrochloride) First | Reference (Mirapex®) First | Total |
|---|---|---|---|
| United States | 12 | 12 | 24 |
The record gives a start of Feb 2005, a primary completion of Mar 2005 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole